Critical Care
RCT: A Seven-days course of antibiotics for the treatment of bloodstream infections by Enterobacterales was noninferior to a 14-days course.
9 Sep, 2021 | 09:03h | UTC
Commentary on Twitter
SHORTEN RCT ???@CMIJournal
Seven versus 14-days course of antibiotics for the treatment of bloodstream infections by Enterobacterales
7-day course of antibiotics as the preferential treatment for eBSI, as long as the source is properly controlled https://t.co/pyaOMl52us pic.twitter.com/wK1sgeMe36— Antibiotic Steward ??? Bassam Ghanem (@ABsteward) September 8, 2021
Review: Management of severe traumatic brain injury in regions with limited resources.
9 Sep, 2021 | 08:56h | UTCManagement of severe traumatic brain injury in regions with limited resources – Brain Injury
Cochrane review: evidence is insufficient to draw meaningful conclusions if SARS‐CoV‐2-specific monoclonal antibodies are effective in the treatment of COVID-19.
7 Sep, 2021 | 21:51h | UTCOriginal review: SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 – Cochrane Library
Supplement: Current Issues in Venous Thromboembolism.
7 Sep, 2021 | 21:36h | UTCHomepage: Current Issues in Venous Thromboembolism – Postgraduate Medicine
Editorial: Current issues in venous thromboembolism
A review of upper extremity deep vein thrombosis
Outpatient treatment of emergency department patients diagnosed with venous thromboembolism
Venous thromboembolism prophylaxis in high-risk orthopedic and cancer surgery
Prophylaxis and treatment of COVID-19 related venous thromboembolism
Challenges in the diagnostic approach of suspected pulmonary embolism in COVID-19 patients
Post-hospital discharge venous thromboembolism prophylaxis in medically ill patients
Radiologic mimics of pulmonary embolism
A comprehensive review of DOACs for cancer associated VTE prophylaxis or treatment
Isn’t it time to abandon ARDS? The COVID-19 lesson.
7 Sep, 2021 | 21:34h | UTCIsn’t it time to abandon ARDS? The COVID-19 lesson – Critical Care
Commentary on Twitter
#CritCare #OA #Gattinoni & #Marini: Keeping or abandoning #ARDS?
▶️ pros
▶️ conshttps://t.co/tIhusXT2S7#FOAMed #FOAMcc #BMC #COVID19 #Rx #RCT #PEEP #respiratory_failure #Personalized pic.twitter.com/M6aoiSAn3m— Critical Care (@Crit_Care) September 7, 2021
Annual Update in Intensive Care and Emergency Medicine 2021 – Covid articles.
7 Sep, 2021 | 10:50h | UTCSecondary infections in critically ill patients with COVID-19
Tracheostomy for COVID-19: evolving best practice
See also: Non-Covid articles
Case series: COVID-19 mRNA vaccination leading to CNS inflammation.
7 Sep, 2021 | 10:49h | UTCCOVID-19 mRNA vaccination leading to CNS inflammation: a case series – Journal of Neurology
Medical, ethical, and legal aspects of end-of-life dilemmas in the intensive care unit.
7 Sep, 2021 | 10:37h | UTC
Cohort study: Serum markers of brain injury can predict good neurological outcome after out-of-hospital cardiac arrest.
7 Sep, 2021 | 10:41h | UTC
Commentary on Twitter
Established/novel blood brain injury markers early predict good neuro-outcome/absence of pathological prognostic findings post CA
?NSE/S100B may prevent premature WLST
?NFL highest predictive capacity
Here visual abstract, full results #FOAMcc @yourICM https://t.co/3klcew33bD pic.twitter.com/1agsFCw6RF— Intens Care Med (@yourICM) September 4, 2021
Annual Update in Intensive Care and Emergency Medicine 2021 – Non-Covid articles.
7 Sep, 2021 | 10:43h | UTCAdvanced management of intermediate-high risk pulmonary embolism
Pathophysiology and clinical implications of the veno-arterial PCO2 gap
To prone or not to prone ARDS patients on ECMO
Management of acute metabolic acidosis in the ICU: sodium bicarbonate and renal replacement therapy
Acute kidney injury in ECMO patients
Still a place for aortic counterpulsation in cardiac surgery and patients with cardiogenic shock?
See also: Covid articles
Podcast: The Best of Liver Tests.
7 Sep, 2021 | 10:29h | UTC#293 The Best of Liver Tests with Dr. Elliot Tapper – The Curbsiders
RCT: Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels.
6 Sep, 2021 | 11:11h | UTC
Commentary on Twitter
The SAVE-MORE phase 3 study demonstrates the efficacy of anakinra, an IL-1α/β inhibitor, in patients with COVID-19 and high serum levels of soluble plasminogen activator receptor, according to a @NatureMedicine paper. https://t.co/aM5teLMipK pic.twitter.com/bTVNqbBOcv
— Nature Portfolio (@NaturePortfolio) September 3, 2021
Study shows cardiac troponin concentrations at presentation are insufficient to distinguish type 1 myocardial infarction from other causes of myocardial injury.
6 Sep, 2021 | 10:42h | UTC
Commentary on Twitter
Cardiac troponin release kinetics: levels at presentation cannot distinguish type 1 MI from other causes of injury or infarction. Results now online @CircAHA https://t.co/8cjyl6SGai@HighSTEACS @chapdoc1 @djlmed @DorienKimenai @EdinUniCVS pic.twitter.com/v0RoD532Jx
— Ryan Wereski (@RyanWereski) June 25, 2021
Musculoskeletal complications following critical illness: A scoping review.
3 Sep, 2021 | 10:07h | UTC
Commentary on Twitter
Very pleased that our scoping review on MSK complications following critical illness has been published – first paper from my PhD! @mawilliamsinOx @helendawes2 @matthewjrowland @ouh_therapies @MOReS_OBU #icurehab https://t.co/f6kHDtMzrj pic.twitter.com/bOm3YvLP5U
— Owen Gustafson (@OxfordICUPhysio) August 26, 2021
RCT: Baricitinib reduced mortality in hospitalized adults with COVID-19.
2 Sep, 2021 | 10:17h | UTCCommentaries:
Commentaries on Twitter
NEW—Baricitinib did not improve the composite primary endpoint of progression to NIV,
high-flow O2, IMV, or death; however, it did reduce 28-day all-cause mortality by 38·2% vs placebo (HR 0·57 [95% CI 0·41–0·78])Read the COV-BARRIER study: https://t.co/QrU6GW0XcQ#ISICEM2021
— The Lancet Respiratory Medicine (@LancetRespirMed) September 1, 2021
(thread – click for more)
1/?? NEW COVID THERAPY SAVES LIVES
Adding baricitinib to steroids will save 1,000s of hospitalized #COVID pts. Our @LancetRespirMed COV-Barrier study is FREE.
I explain?why it’s such a great #Pandemic discovery story: a new way to ⬇️ COVID19 deaths.https://t.co/8I5BlwyT2R pic.twitter.com/6KcfQrljqC
— WesElyMD (@WesElyMD) September 1, 2021
Scientific Statement: Coronavirus Disease-2019 and Heart Failure.
2 Sep, 2021 | 10:08h | UTC
Commentary on Twitter
Released today: Coronavirus Disease-2019 and Heart Failure: A Scientific Statement from @HFSA, published in @JCardFail. @dranulala @ankeetbhatt @EricAdler17 @BhadeliaMD @AshishCorrea @ersied727 @heartofthemater @AndrewJSauer @NMHheartdoc @scottdsolomon https://t.co/fyWab32ruU pic.twitter.com/8pNY60I6gD
— HFSA (@HFSA) September 1, 2021
RCT: Among critically ill patients, targeting oxygenation to a low-normal range vs. high-normal range did not result in a reduction in organ dysfunction.
2 Sep, 2021 | 08:23h | UTCEffect of Low-Normal vs High-Normal Oxygenation Targets on Organ Dysfunction in Critically Ill Patients: A Randomized Clinical Trial – JAMA (free for a limited period)
Related:
M-A of randomized trials: Conservative oxygen therapy for critically ill patients.
Oxygen administration for patients with ARDS – Journal of Intensive Care
Commentary on Twitter
Multicenter RCT found, among critically ill patients, targeting oxygenation to a low-normal range compared with a high-normal range did not result in a statistically significant reduction in organ dysfunction https://t.co/lEq28bqmM4 #ISICEM21
— JAMA (@JAMA_current) August 31, 2021
RCT: In patients with acute hypoxemic respiratory failure, a strategy of lower tidal volume ventilation facilitated by extracorporeal carbon dioxide removal was not associated with improved outcomes.
2 Sep, 2021 | 08:21h | UTCEffect of Lower Tidal Volume Ventilation Facilitated by Extracorporeal Carbon Dioxide Removal vs Standard Care Ventilation on 90-Day Mortality in Patients With Acute Hypoxemic Respiratory Failure: The REST Randomized Clinical Trial – JAMA (free for a limited period)
Related: Randomized Trial: Low vs Intermediate Tidal Volume Strategy in ICU Patients Without ARDS
Commentary on Twitter
In this randomized clinical trial that included 412 adults, 90-day mortality was 41.5% in the extracorporeal carbon dioxide removal group and 39.5% in the standard care group, a difference that was not statistically significant https://t.co/jhCY2r4qjX #ISICEM21
— JAMA (@JAMA_current) August 31, 2021
Review: Initial antimicrobial management of sepsis – immediate, empiric, broad-spectrum therapy is key, but it must be accompanied by a commitment to de-escalation and antimicrobial stewardship.
1 Sep, 2021 | 08:59h | UTCInitial antimicrobial management of sepsis – Critical Care
#ESCCongress – RCT: Influenza vaccination early after a myocardial infarction (MI) or in high-risk coronary heart disease resulted in a lower risk of a composite of all-cause death, MI, or stent thrombosis compared with placebo.
31 Aug, 2021 | 08:52h | UTCCommentaries:
IAMI: Influenza Vaccine Beneficial for Post-MI Patients – TCTMD
Influenza Vaccination After Myocardial Infarction – IAMI – American College of Cardiology
Flu vaccine after heart attack reduces risk of death – Cardiovascular Business
Commentary on Twitter
The IAMI trial showed that #fluvaccine within 72 hours of angiography/PCI/hospitalization among patients with recent #cvMI or high-risk coronary heart disease resulted in a salutary effect on CV outcomes at 12 months compared w/ placebo: https://t.co/csnS3G8vsa #ESCCongress pic.twitter.com/5JB4iUmMbV
— American College of Cardiology (@ACCinTouch) August 30, 2021
Cohort study: Patients with Covid-19 infected with the Delta variant are twice as likely to need hospital admission or emergency care attendance.
29 Aug, 2021 | 19:02h | UTCCommentaries:
Covid: Delta variant patients twice as likely to need hospital care – BBC
Covid-19 hospitalization risk doubles with Delta variant, UK study suggests – CNN
Commentary on Twitter
The Delta variant is bad enough, but there has been debate as to whether it, per se, carries a higher risk of hospitalization (H) beyond its very high contagiousness. A new, rigorous study shows a doubling of the H rate https://t.co/qom8l6fw4v pic.twitter.com/CwXPOU0YWi
— Eric Topol (@EricTopol) August 27, 2021
#ESCCongress – RCT: Immediate coronary angiography after out-of-hospital cardiac arrest without ST-segment elevation did not improve outcomes compared to delayed/selective angiography.
29 Aug, 2021 | 18:12h | UTCNews release: Trial does not support early coronary angiography in cardiac arrest without ST elevation – European Society of Cardiology
Commentaries:
Commentary on Twitter
TOMAHAWK: In patients without ST elevation and OHCA, immediate coronary angiography provided no benefit over delayed. #ESCCongress https://t.co/7IKJ1y4B8v pic.twitter.com/H0cyyl18ig
— NEJM (@NEJM) August 29, 2021
COVID-19 associated Mucormycosis: risk factors and mechanisms of disease.
27 Aug, 2021 | 10:07h | UTCRelated: Clinical Picture: Mucormycosis after COVID-19 in a patient with diabetes. (several articles on the subject)
Commentary on Twitter
???Review Article #CID @IDSAInfo @jobadd
COVID-19 associated Mucormycosis (CAM): risk factors and mechanisms of disease #IDTwitter #medtwitter #TwitteRx https://t.co/Ob89SFNoPx pic.twitter.com/tzf7KpGVyG— Antibiotic Steward ??? Bassam Ghanem (@ABsteward) August 22, 2021
M-A: Physical rehabilitation in the ICU improves physical function and reduces ICU and hospital length of stay.
27 Aug, 2021 | 09:02h | UTCPhysical Rehabilitation in the ICU: A Systematic Review and Meta-Analysis – Critical Care Medicine (link to abstract – $ for full-text)
M-A of randomized trials: Effectiveness of the modified Valsalva maneuver in adults with supraventricular – “The meta-analysis demonstrated a significantly higher success rate for reconversion to sinus rhythm when using the modified VM compared to the standard VM in patients with an SVT (odds ratio = 4.36; 95% confidence interval, 3.30–5.76; P < 0.001)”.
26 Aug, 2021 | 08:51h | UTCEffectiveness of the modified Valsalva manoeuvre in adults with supraventricular tachycardia: a systematic review and meta-analysis – European Journal of Emergency Medicine (link to abstract – $ for full-text)
Related: Randomized Trial: Standard Valsalva vs. Modified Valsalva for Cardioversion of SVT (studies and commentaries on the subject)
Video: Modified Valsalva manoeuvre for supraventricular tachycardia – The Lancet